N-cyclobutylmethyl analog of normorphinone, N-CBM-TAMO: A short-term opioid agonist and long-term mu-selective irreversible opioid antagonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 279, Issue 2, 1996, Pages 539-547

  Xu, Jimmy Yu ^a   Seyed Mozaffari, Ahmad ^b   Archer, Sydney ^b   Bidlack, Jean M ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b RENSSELAER POLYTECHNIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

14ALPHA,14'BETA [DITHIOBIS[(2 OXO 2,1 ETHANEDIYL)IMINO]]BIS[7,8 DIHYDRO N (CYCLOBUTYLMETHYL) NORMORPHINONE]; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; BETA FUNALTREXAMINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE 4 (4 CHLOROPHENYLALANINE)]; KAPPA OPIATE RECEPTOR AGONIST; MORPHINE SULFATE; MORPHINONE; MU OPIATE RECEPTOR ANTAGONIST; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; N,N DIALLYLTYROSYL 2 METHYLALANYL 2 METHYLALANYLPHENYLALANYLLEUCINE; NORBINALTORPHIMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CATTLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; RECEPTOR AFFINITY; STRIATE CORTEX; TAIL FLICK TEST; WRITHING TEST;

ANALGESICS, OPIOID; ANIMALS; BENZENEACETAMIDES; CATTLE; DOSE-RESPONSE RELATIONSHIP, DRUG; HYDROMORPHONE; MALE; MICE; MICE, INBRED ICR; MORPHINE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PYRROLIDINES; RECEPTORS, OPIOID, MU;

EID: 0030425425     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. ACETO, M. D., DEWEY, W. L., PORTOGHESE, P. S. AND TAKEMORI, A. E.: Effects of β-funaltrexamine (β-FNA) on morphine dependence in rats and monkeys. Eur. J. Pharmacol. 123: 387-393, 1986.
2. 1 antagonist (AS-300). Bioorg. Med. Chem. Lett. 6: 1139-1144, 1996.
3. ARCHER, S., SEYED-MOZAFFARI, A., JIANG, Q. AND BIDLACK, J. M.: 14α,14′β-[Dithiobis[(2-oxo-2,1-ethanediyl)imino]]bis(7,8- dihydromorphinone) and 14α,14′β-[Dithiobis[(2-oxo-2,1-ethanediyl)imino]]bis[7,8- dihydro-N-(cyclopropylmethyl) normorphinone]: Chemistry and opioid binding properties. J. Med. Chem. 37: 1578-1585, 1994.
4. BHARGAVA, H. N., GULATI, A. AND RAMAKAO, P.: Effect of chronic administration of U-50,488H on tolerance to its pharmacological actions and on multiple opioid receptors in rat brain regions and spinal cord. J. Pharmacol. Exp. Ther. 251: 21-26, 1989.
5. BIDLACK, J. M., FREY, D. K., KAPLAN, R. A., SEYED-MOZAFFARI, A. AND ARCHER, S.: Affinity labeling of μ opioid receptors by sulfhydryl alkylating derivatives of morphine and morphinone. Mol. Pharmacol. 37: 50-59, 1990.
6. BIDLACK, J. M., SEYED-MOZAFFARI, A. AND ARCHER, S.: 14β-Thioglycolamido-7,8-dihydromorphinone, a μ-selective irreversible ligand. Med. Chem. Res. 1: 43-46, 1991.
7. 8]enkephalin: covalent attachment via thiol-disulfide exchange. J. Biol. Chem. 262:13434-13439, 1987.
8. BRADFORD, M. M.: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254, 1976.
9. COWAN, A. AND MURRAY, C. W.: Effect of nor-binaltorphimine on the behavior of mice and rats receiving multiple injections of U-50,488H. Prog. Clin. Biol. Res. 328: 303-306, 1990.
10. DEVINE, D. P., LEONE, P., POCOCK, D. AND WISE, R. A.: Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies. J. Pharmacol. Exp. Ther. 266: 1236-1246, 1993.
11. DI CHIARA, G. AND IMPERATO, A.: Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. U.S.A. 85: 5274-5278, 1988.
12. ERRICK, J. K. AND HEEL, R. C.: Nalbuphine: A preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 26: 191-211, 1983.
13. GIOANNINI, T. L., LIU, Y. F., PARK, Y.-H., HILLER, J. M. AND SIMON, E. J.: Evidence for the presence of disulfide bridges in opioid receptors essential for ligand binding. Possible role in receptor activation. J. Mol. Recogit. 2: 44-48, 1989.
14. GLICK, S. D., MAISONNEUVE, I. M., RAUCCI, J. AND ARCHER, S.: Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Res. 681: 147-152, 1995.
15. HALEY, T. J. AND MCCORMICK, W. G.: Pharmacological effects produced by intracerebral injections of drugs in the conscious mouse, Br. J. Pharmacol. Chemother. 12: 12-15, 1957.
16. 2-adrenergic receptors in rat brain. Nature 291: 493-495, 1981.
17. HEEL, R. C., BROGDEN, R. N., SPEIGHT, T. M. AND AVERY, G. S.: Butorphanol: A review of its pharmacological properties and therapeutic efficacy. Drugs 16: 473-505, 1978.
18. HEIN, D. W., YOUNG, A. M., HERLING, S. AND WOODS, J. H.: Pharmacological analysis of the discriminative stimulus characteristics of ethylketazocine in the rhesus monkey. J. Pharmacol. Exp. Ther. 218: 7-15, 1981.
19. ISBELL, H.: The search for the nonaddicting analgesic: Has it been worth it? Clin. Pharmacol. Ther. 22: 377-384, 1977.
20. JASINSKI, D. R.: Human pharmacology of narcotic antagonists. Br. J. Clin. Pharmacol. 7: suppl. 3, 287S-290S, 1979.
21. JASINSKI, D. R. AND MANSKY, P. A.: Evaluation of nalbuphine for abuse potential. Clin. Pharmacol. Ther. 13: 78-90, 1972.
22. JIANG, Q., SEYED-MOZAFFARI, A., ARCHER, S. AND BIDLACK, J. M.: Pharmacological study of 14β-(thioglycolamido)-7,8-dihydro-N(cyclopropylmethyl)-normorphinone (N-CPM-TAMO). J. Pharmacol. Exp. Ther. 264: 1021-1027, 1993.
23. 2BAMO). J. Pharmacol. Exp. Ther. 262: 526-531, 1992.
24. JIANG, Q., SEYED-MOZAFFARI, A., SEBASTIAN, A., ARCHER, S. AND BIDLACK, J. M.: Preventing morphine antinociceptive tolerance by irreversible mu opioid antagonists before the onset of their antagonism. J. Pharmacol. Exp. Ther. 273: 680-688, 1995.
25. KIRBY, G. W. AND MCLEAN, D.: J. Chem. Soc. Perkin Trans. I 1443-1445, 1985.
26. LEANDER, J. D.: Evidence that nalorphine, butorphanol and oxilorphan are partial agonists at a kappa-opioid receptor. Eur. J. Pharmacol. 86:467-470, 1983.
27. LLORENS, C., MARTRES, M. P., BAUDRY, M. AND SCHWARTZ, J. C.: Hypersensitivity to noradrenaline in cortex after chronic morphine: Relevance to tolerance and dependence. Nature 274: 603-605, 1978.
28. MAISONNEUVE, I. M., ARCHER, S. AND GLICK, S. D.: U50488, a κ opioid agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci. Lett. 181: 57-60, 1994.
29. MARTIN, W. R. AND GORODETZKY, C. W.: Demonstration of tolerance to and physical dependence on N-allylnormorphine (nalorphine). J. Pharmacol. Exp. Ther. 160: 437-442, 1965.
30. MUNSON, P. J. AND RODBARD, D.: LIGAND: A versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 107: 220-239, 1980.
31. NEGUS, S. S., HENRIKSEN, S. J., MATTOX, A., PASTERNAK, G. W., PORTOGHESE, P. S., TAKEMORI, A. E., WEINGER, M. B. AND KOOB, G. F.: Effect of antagonists selective for mu, delta and kappa opioid receptors on the reinforcing effects of heroin in rats. J. Pharmacol. Exp. Ther. 265: 1245-1252, 1993.
32. 3 analgesic in mice. J. Pharmacol. Exp. Ther. 262: 1044-1050, 1992.
33. 6]enkephalin in the mouse. J. Pharmacol. Exp. Ther. 241: 393-400, 1987.
34. PORTOGHESE, P. S., LARSON, D. L., JIANG, J. B., CARUSO, T. P. AND TAKEMORI, A. E.: Synthesis and pharmacological characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties. J. Med. Chem. 22: 168-173, 1979.
35. SCHIMDT, W. K., TAM, S. W., SHOTZBERGER, G. S., SMITH, D. H., J. R., CLARK, R. AND VERNIER, V. G.: Nalbuphine. Drug Alcohol Depend. 14: 339-362, 1985.
36. SCHULZ, R. AND HERZ, A: Naloxone-precipitated withdrawal reveals sensitization to neurotransmitters in morphine tolerant/dependent rats. Naunyn Schmiedeberg's Arch Pharmacol. 299: 95-99, 1977.
37. SEBASTIAN, A., BIDLACK, J. M., JIANG, Q., DEECHER, D., TEITLER, M., GLICK, S. D. AND ARCHER, S.: 14β-p-nitrocinnamoylamino-7,8-dihydromorphinones and their codeinone analogues: Synthesis and receptor activity, J. Med. Chem. 36: 3154-3160, 1993.
38. SEEVERS, M. H. AND DENEAU, G. A.: A critique of the "dual action" hypothesis of morphine physical dependence. Arch. Int. Pharmacodyn. Ther. 140: 514-520, 1962.
39. SPANAGEL, R., HERZ, A. AND SHIPPENBERG, T. S.: Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc. Natl. Acad. Sci. U.S.A. 89: 2046-2050, 1992.
40. SPEALMAN, R. D. AND BERGMAN, J.: Modulation of the discriminative stimulus effects of cocaine by mu and kappa opioids. J. Pharmacol. Exp. Ther. 261: 607-615, 1992.
41. TAKEMORI, A. E., HO, B. Y., NAESETH, J. S. AND PORTOGHESE, P. S.: Norbinaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J. Pharmacol. Exp. Ther. 246: 255-258, 1988.
42. TALLARIDA, R. J. AND MURRAY, R. B.: Manual of Pharmacologic Calculations with Computer Programs, 2nd ed., Springer-Verlag, New York, 1986.
43. THOMPSON, R. C., MANSOUR, A., AKIL, H. AND WATSON, S. J.: Cloning and characterization of a rat μ opiod receptor. Neuron 11: 903-913, 1993.
44. VAUGHT, J. L. AND TAKEMORI, A. E.: Differential effects of leucine and methionine enkephalin on morphine-induced analgesia, acute tolerance and dependence. J. Pharmacol. Exp. Ther. 208: 86-90, 1979.
45. WOODS, J. H., FRANCE, C. P., BERTALMIO, A. J., GMEREK, D. E. AND WINGER, G.: Behavioral assessment of insurmountable narcotic agonists and antagonists. In Behavioral Pharmacology: The Current Status, ed. by L. S. Seiden and R. L. Balster, pp. 76-92, Alan Lisa, New York, NY, 1985.
46. YANO, I. AND TAKEMORI, A. E.: Inhibition by naloxone of tolerance and dependence in mice treated acutely and chronically with morphine. Res. Commun. Chem. Pathol. Pharmacol. 18: 721-734, 1977.